28,245 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Curat Global LLC

Curat Global LLC acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 28,245 shares of the biopharmaceutical company's stock, valued at approximately $716,000.

Several other large investors also recently bought and sold shares of PFE. Signal Advisors Wealth LLC grew its stake in shares of Pfizer by 16.6% during the 1st quarter. Signal Advisors Wealth LLC now owns 8,826 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 1,258 shares during the period. Foster Group Inc. grew its stake in shares of Pfizer by 2.9% during the 1st quarter. Foster Group Inc. now owns 27,869 shares of the biopharmaceutical company's stock valued at $706,000 after purchasing an additional 780 shares during the period. Vest Financial LLC grew its stake in shares of Pfizer by 73.5% during the 1st quarter. Vest Financial LLC now owns 47,252 shares of the biopharmaceutical company's stock valued at $1,197,000 after purchasing an additional 20,018 shares during the period. Breakwater Capital Group grew its stake in shares of Pfizer by 4.3% during the 1st quarter. Breakwater Capital Group now owns 76,325 shares of the biopharmaceutical company's stock valued at $1,934,000 after purchasing an additional 3,144 shares during the period. Finally, Charles Schwab Trust Co purchased a new position in shares of Pfizer during the 1st quarter valued at about $224,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PFE. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.24 during trading on Friday, reaching $23.36. 30,404,818 shares of the stock traded hands, compared to its average volume of 40,962,579. The company has a market capitalization of $132.81 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57. The business has a fifty day simple moving average of $22.97 and a two-hundred day simple moving average of $25.01. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.82 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.36%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.